Gland Pharma Limited (BOM:543245)
India · Delayed Price · Currency is INR 2,200.95
+3.80 (0.17%)
At close: Jun 18, 2026
Gland Pharma Stock Forecast
Stock Price Forecast
According to 14 analysts polled by S&P Global, Gland Pharma stock has a consensus rating of "Buy" and an average price target of ₹2,190. The average 1-year stock price forecast is 0.52% lower than the current stock price, while the lowest is ₹1,630 (-25.94%) and the highest is ₹2,645 (+20.18%).
Price Target: ₹2,190 (-0.52%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Gland Pharma stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '25 | Jan '26 | Feb '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 5 | 5 | 5 | 7 | 7 |
| Buy | 3 | 3 | 2 | 2 | 3 | 3 |
| Hold | 2 | 1 | 1 | 1 | 1 | 1 |
| Sell | 1 | 1 | 2 | 2 | 0 | 0 |
| Strong Sell | 3 | 3 | 3 | 3 | 3 | 3 |
| Total | 12 | 13 | 13 | 13 | 14 | 14 |
Financial Forecast
Revenue This Year
73.77B
from 64.31B
Increased by 14.71%
Revenue Next Year
83.11B
from 73.77B
Increased by 12.67%
EPS This Year
74.91
from 63.01
Increased by 18.88%
EPS Next Year
91.25
from 74.91
Increased by 21.81%
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is INR.
Revenue Forecast
| Revenue | 2027 | 2028 | 2029 |
|---|---|---|---|
| High | 76.7B | ||
| Avg | 73.8B | ||
| Low | 71.4B |
Revenue Growth
| Revenue Growth | 2027 | 2028 | 2029 |
|---|---|---|---|
| High | 19.3% | ||
| Avg | 14.7% | ||
| Low | 11.1% |
EPS Forecast
| EPS | 2027 | 2028 | 2029 |
|---|---|---|---|
| High | - | ||
| Avg | 74.91 | ||
| Low | - |
EPS Growth
| EPS Growth | 2027 | 2028 | 2029 |
|---|---|---|---|
| High | - | ||
| Avg | 18.9% | ||
| Low | - |